The percentage of patients in the PARA cohort, a historic reference cohort (2002–2010), using certain medication during pregnancy (total number of patients=253)
| Medication | Before pregnancy visit n (%) N=124 | 1st trimester visit n (%) N=213 | 2nd trimester visit n (%) N=232 | 3rd trimester visit n (%) N=245 | 6 weeks postpartum visit n (%) N=239 | 12 weeks postpartum visit n (%) N=240 | 26 weeks postpartum visit n (%) N=222 |
| Methotrexate | 0 | 0 | 0 | 0 | 45 (18.8) | 73 (30.4) | 89 (40.0) |
| Leflunomide | 0 | 0 | 0 | 0 | 0 | 3 (1.3) | 4 (1.8) |
| Hydroxychloroquine | 8 (6.5) | 5 (2.3) | 5 (2.2) | 4 (1.6) | 10 (4.2) | 19 (7.9) | 18 (8.1) |
| Sulfasalazine | 42 (33.9) | 61 (28.6) | 65 (28.0) | 63 (25.7) | 64 (26.8) | 73 (30.4) | 70 (31.5) |
| Prednisone | 52 (41.9) | 80 (37.6) | 87 (37.5) | 87 (35.5) | 85 (35.6) | 89 (37.1) | 78 (35.1) |
| Azathioprine | 2 (1.6) | 1 (0.5) | 1 (0.4) | 1 (0.4) | 3 (1.3) | 2 (0.8) | 2 (0.9) |
| Adalimumab | 0 | 0 | 0 | 0 | 5 (2.1) | 7 (2.9) | 12 (5.4) |
| Infliximab | 0 | 0 | 0 | 0 | 1 (0.4) | 2 (0.8) | 3 (1.4) |
| Etanercept | 0 | 0 | 0 | 0 | 7 (2.9) | 14 (5.8) | 13 (5.9) |
The medication that is not listed in this table was not prescribed during this study period.